Email this article Effects of Release-Active Antibodies to CD4 Receptor on the Level of lck-Kinase in Cultured Mononuclear Cells from Human Peripheral Blood
- Authors: Emel’yanova A.G.1, Grechenko V.V.2, Petrova N.V.1, Shilovskii I.P.3, Gorbunov E.A.2, Tarasov S.A.2, Khaitov M.R.3, Morozov S.G.1, Epshtein O.I.1
-
Affiliations:
- 1Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathophysiology, Research Institute of General Pathology and Pathophysiology
- Research and Production Company Materia Medica Holding
- State Research Centre Institute of Immunology, Federal Medical-Biological Agency of the Russian Federation
- Issue: Vol 162, No 3 (2017)
- Pages: 323-326
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/238168
- DOI: https://doi.org/10.1007/s10517-017-3606-4
- ID: 238168
Cite item
Open Access
Access granted
Subscription Access
Abstract
For evaluation of effects of release-active antibodies to CD4 on cultured lymphocytes from human peripheral blood, we measured intracellular content of lck-kinase cell-based ELISA. In cells treated with release-active antibodies to CD4, the content of intracellular lck-kinase significantly (p<0.01) decreased in comparison with the control (purified water processed in a similar way). Phytohemagglutinin had no effect on the concentration of lck-kinase in cells. The decrease in the content of CD4-associated lck protein suggests that the preparation enhanced intracellular coupling of lck-kinase with T-cell receptor and potentiated T-cell immune response.
About the authors
A. G. Emel’yanova
1Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathophysiology, Research Institute of General Pathology and Pathophysiology
Author for correspondence.
Email: agemelyanova@gmail.com
Russian Federation, Moscow
V. V. Grechenko
Research and Production Company Materia Medica Holding
Email: agemelyanova@gmail.com
Russian Federation, Moscow
N. V. Petrova
1Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathophysiology, Research Institute of General Pathology and Pathophysiology
Email: agemelyanova@gmail.com
Russian Federation, Moscow
I. P. Shilovskii
State Research Centre Institute of Immunology, Federal Medical-Biological Agency of the Russian Federation
Email: agemelyanova@gmail.com
Russian Federation, Moscow
E. A. Gorbunov
Research and Production Company Materia Medica Holding
Email: agemelyanova@gmail.com
Russian Federation, Moscow
S. A. Tarasov
Research and Production Company Materia Medica Holding
Email: agemelyanova@gmail.com
Russian Federation, Moscow
M. R. Khaitov
State Research Centre Institute of Immunology, Federal Medical-Biological Agency of the Russian Federation
Email: agemelyanova@gmail.com
Russian Federation, Moscow
S. G. Morozov
1Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathophysiology, Research Institute of General Pathology and Pathophysiology
Email: agemelyanova@gmail.com
Russian Federation, Moscow
O. I. Epshtein
1Laboratory of Physiologically Active Substances, Department of Molecular and Cellular Pathophysiology, Research Institute of General Pathology and Pathophysiology
Email: agemelyanova@gmail.com
Russian Federation, Moscow
